PMID- 20441964
OWN - NLM
STAT- MEDLINE
DCOM- 20101021
LR  - 20181201
IS  - 1873-3573 (Electronic)
IS  - 0039-9140 (Linking)
VI  - 81
IP  - 4-5
DP  - 2010 Jun 15
TI  - Development of a fluorescent anti-factor Xa assay to monitor unfractionated and 
      low molecular weight heparins.
PG  - 1725-30
LID - 10.1016/j.talanta.2010.03.030 [doi]
AB  - Fluorogenic assays have many potential advantages over traditional clot-based and 
      chromogenic assays such as the absence of interference from a range of factor 
      deficiencies as well as offering the possibility of assays in platelet rich 
      plasma or whole blood. A fluorogenic anti-factor Xa (anti-FXa) assay has been 
      developed for the determination of unfractionated heparin (UFH), low molecular 
      weight heparins (LMWHs), namely enoxaparin and tinzaparin, and the synthetic 
      heparinoid danaparoid, in commercial human pooled plasma. The assay was based on 
      the complexation of heparin-spiked plasmas with exogenous FXa at a concentration 
      of 4nM in the presence of 0.9microM of the fluorogenic substrate 
      methylsulfonyl-D-cyclohexylalanyl-glycyl-arginine-7-amino-4-methylcoumarin 
      acetate (Pefafluor FXa). Pooled plasma samples were spiked with concentrations of 
      anticoagulants in the range 0-1.6U/ml. The assay was capable of the measurement 
      of UFH and danaparoid in the range 0-1U/ml, and enoxaparin and tinzaparin in the 
      range 0-0.8 and 0-0.6U/ml, respectively. Correlation coefficients generated by 
      linear regression of the log/lin data analysis were between 0.93 and 0.96 for the 
      anticoagulants tested. Assay percentage coefficients of variation were typically 
      below 7%.
FAU - Harris, Leanne F
AU  - Harris LF
AD  - Biomedical Diagnostics Institute, National Centre for Sensor Research, Dublin 
      City University, Dublin 9, Ireland.
FAU - Castro-Lopez, Vanessa
AU  - Castro-Lopez V
FAU - Hammadi, Nissrin
AU  - Hammadi N
FAU - O'Donnell, James S
AU  - O'Donnell JS
FAU - Killard, Anthony J
AU  - Killard AJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100325
PL  - Netherlands
TA  - Talanta
JT  - Talanta
JID - 2984816R
RN  - 0 (Anticoagulants)
RN  - 0 (Enoxaparin)
RN  - 0 (Fluorescent Dyes)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Heparinoids)
RN  - 24967-94-0 (Dermatan Sulfate)
RN  - 7UQ7X4Y489 (Tinzaparin)
RN  - 9005-49-6 (Heparin)
RN  - 9007-28-7 (Chondroitin Sulfates)
RN  - 9050-30-0 (Heparitin Sulfate)
RN  - BI6GY4U9CW (danaparoid)
RN  - EC 3.4.21.6 (Factor Xa)
SB  - IM
MH  - Anticoagulants/chemistry
MH  - Chemistry Techniques, Analytical
MH  - Chondroitin Sulfates/chemistry
MH  - Dermatan Sulfate/chemistry
MH  - Dose-Response Relationship, Drug
MH  - Enoxaparin/chemistry
MH  - Factor Xa/*chemistry/isolation & purification
MH  - Fluorescent Dyes
MH  - Heparin/*analysis/chemistry
MH  - Heparin, Low-Molecular-Weight/*analysis/chemistry
MH  - Heparinoids/chemistry
MH  - Heparitin Sulfate/chemistry
MH  - Humans
MH  - Kinetics
MH  - Reproducibility of Results
MH  - Software
MH  - Tinzaparin
EDAT- 2010/05/06 06:00
MHDA- 2010/10/22 06:00
CRDT- 2010/05/06 06:00
PHST- 2009/11/12 00:00 [received]
PHST- 2010/03/09 00:00 [revised]
PHST- 2010/03/18 00:00 [accepted]
PHST- 2010/05/06 06:00 [entrez]
PHST- 2010/05/06 06:00 [pubmed]
PHST- 2010/10/22 06:00 [medline]
AID - S0039-9140(10)00224-9 [pii]
AID - 10.1016/j.talanta.2010.03.030 [doi]
PST - ppublish
SO  - Talanta. 2010 Jun 15;81(4-5):1725-30. doi: 10.1016/j.talanta.2010.03.030. Epub 
      2010 Mar 25.